REAL-WORLD OUTCOMES AMONG AML PATIENTS TREATED WITH DECITABINE OR AZACITIDINE

被引：0
|
作者：
Smith, B. [1 ]
Beach, C. [2 ]
Mahmoud, D. [3 ]
Weber, L. [3 ]
Henk, H. [4 ]
机构：
[1] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Hematol Oncol Clin Reserch & Dev, Summitt, NJ USA
[3] Celgene, Global Pricing & Market Access, Summitt, NJ USA
[4] Optum, Eden Prairie, MN USA
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P047
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [1] Real-world outcomes among AML patients treated with decitabine or azacitidine
    Smith, B. D.
    Beach, C. L.
    Mahmoud, D.
    Weber, L.
    Henk, H.
    LEUKEMIA RESEARCH, 2013, 37 : S109 - S109
  • [2] Real-world outcomes in patients with AML and MDS treated with Azacitidine
    Prusak, E.
    Lawes, M.
    Collins, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 42 - 42
  • [3] Real-World Outcomes of Decitabine plus Venetoclax With IDH Inhibition for AML
    Kusiel, Justin
    Baratam, Praneeth
    Green, Kimberly
    Coltoff, Alexander
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S297 - S297
  • [4] Outcomes of Induction with Venetoclax in Combination with Decitabine, Azacitidine, or Low-Dose Cytarabine for Treatment of AML: A Real-World Retrospective Analysis
    Bouligny, Ian M.
    Maher, Keri R.
    BLOOD, 2021, 138
  • [5] Real-World Outcomes of IDH Mutant AML Patients Treated with or without IDH Inhibitors
    Al Sbihi, Ali
    Reddy, Sushmitha Nanja
    Dhillon, Vikram
    Lalo, Enxhi
    Ramos, Harry
    Khan, Abdul Moiz
    Balasubramanian, Suresh Kumar
    BLOOD, 2022, 140 : 6189 - 6190
  • [6] Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy
    Zeidan, Amer M.
    Fenaux, Pierre
    Gobbi, Marco
    Mayer, Jiri
    Roboz, Gail J.
    Krauter, Juergen
    Robak, Tadeusz
    Kantarjian, Hagop M.
    Novak, Jan
    Jedrzejczak, Wieslaw W.
    Thomas, Xavier
    Ojeda-Uribe, Mario
    Miyazaki, Yasushi
    Min, Yoo Hong
    Yeh, Su-Peng
    Brandwein, Joseph M.
    Gercheva, Liana
    Demeter, Judit
    Griffiths, Elizabeth A.
    Yee, Karen W. L.
    Issa, Jean-Pierre J.
    Bewersdorf, Jan Philipp
    Keer, Harold
    Hao, Yong
    Azab, Mohammad
    Doehner, Hartmut
    BLOOD, 2022, 140 (03) : 285 - 289
  • [7] Efficacy and Safety Analysis of Venetoclax Combined with Azacitidine in Real-World Treatment of Patients with AML
    Huang, Xin
    Deng, Chengxin
    Li, Minming
    Lu, Zesheng
    Wu, Ping
    Luo, Qiong
    Geng, Suxia
    Zeng, Lingji
    Wang, Yulian
    Zhou, Hui
    Weng, Jianyu
    Du, Xin
    BLOOD, 2023, 142
  • [8] Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience
    Fili, Carla
    Candoni, Anna
    Zannier, Maria Elena
    Olivieri, Jacopo
    Imbergamo, Silvia
    Caizzi, Manuela
    Nadali, Gianpaolo
    Di Bona, Eros
    Ermacora, Anna
    Gottardi, Michele
    Facchinelli, Davide
    Ciancia, Rosanna
    Lazzarotto, Davide
    Dubbini, Maria Vittoria
    Festini, Gianluca
    Gherlinzoni, Filippo
    Michieli, Maria Grazia
    Semenzato, Gianpietro
    Fanin, Renato
    LEUKEMIA RESEARCH, 2019, 76 : 33 - 38
  • [9] Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the 'real-world'
    Mozessohn, Lee
    Cheung, Matthew C.
    Mittmann, Nicole
    Earle, Craig C.
    Liu, Ning
    Buckstein, Rena
    LEUKEMIA & LYMPHOMA, 2020, 61 (06) : 1445 - 1454
  • [10] Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: A real-world, retrospective, claims-based, comparative analysis
    Smith B.D.
    Beach C.L.
    Mahmoud D.
    Weber L.
    Henk H.J.
    Experimental Hematology & Oncology, 3 (1)
12345